实用肝脏病杂志
實用肝髒病雜誌
실용간장병잡지
Journal of Practical Hepatology
2015年
6期
585-589
,共5页
宫嫚%辛绍杰%邹正升%李润东%徐庆会%韩宝英%于建国%于德航%司雁菱%王宪波%候爱画%李秀惠%陈菊梅
宮嫚%辛紹傑%鄒正升%李潤東%徐慶會%韓寶英%于建國%于德航%司雁蔆%王憲波%候愛畫%李秀惠%陳菊梅
궁만%신소걸%추정승%리윤동%서경회%한보영%우건국%우덕항%사안릉%왕헌파%후애화%리수혜%진국매
慢性乙型肝炎%复方鳖甲软肝片%血清肝纤维化指标%临床疗效
慢性乙型肝炎%複方鱉甲軟肝片%血清肝纖維化指標%臨床療效
만성을형간염%복방별갑연간편%혈청간섬유화지표%림상료효
Chronic hepatitis B%Compound Biejia Ruangan Tablet%Serum liver fibrosis index%Clinical curative effect
目的：评估复方鳖甲软肝片治疗慢性乙型肝炎患者对血清肝纤维化指标的影响。方法将304例慢性乙型肝炎分为试验组219例和对照组85例。给予试验组口服复方鳖甲软肝片，对照组口服安络化纤丸，疗程24 w。采用ELISA法检测透明质酸（HA)、黏连蛋白（LN）、Ⅳ型胶原（c-Ⅳ）和Ⅲ型前胶原（PCⅢ）。结果在治疗24 w结束时，经中医症候疗效全分析集（FAS）分析，试验组显效率为72.9%，优于对照组的56.8%（P=0.004）；试验组总有效率为89.3%，优于对照组的80.7%（P=0.029）；试验组血清肝纤维化指标显效率为35.3%，优于对照组的22.2%（P=0.016）；治疗后试验组血清透明质酸（HA）水平下降了（87.4±111.2） ng/mL，优于对照组下降的（61.2±66.2） ng/mL（P=0.01），两组血清LN、c-Ⅳ、PCⅢ水平变化无统计学差异（P>0.05）；两组肝功能指标复常率差异无统计学意义（P＞0.05）；试验组未发现不良反应。结论复方鳖甲软肝片治疗慢性乙型肝炎患者安全、有效，可以改善肝纤维化指标。
目的：評估複方鱉甲軟肝片治療慢性乙型肝炎患者對血清肝纖維化指標的影響。方法將304例慢性乙型肝炎分為試驗組219例和對照組85例。給予試驗組口服複方鱉甲軟肝片，對照組口服安絡化纖汍，療程24 w。採用ELISA法檢測透明質痠（HA)、黏連蛋白（LN）、Ⅳ型膠原（c-Ⅳ）和Ⅲ型前膠原（PCⅢ）。結果在治療24 w結束時，經中醫癥候療效全分析集（FAS）分析，試驗組顯效率為72.9%，優于對照組的56.8%（P=0.004）；試驗組總有效率為89.3%，優于對照組的80.7%（P=0.029）；試驗組血清肝纖維化指標顯效率為35.3%，優于對照組的22.2%（P=0.016）；治療後試驗組血清透明質痠（HA）水平下降瞭（87.4±111.2） ng/mL，優于對照組下降的（61.2±66.2） ng/mL（P=0.01），兩組血清LN、c-Ⅳ、PCⅢ水平變化無統計學差異（P>0.05）；兩組肝功能指標複常率差異無統計學意義（P＞0.05）；試驗組未髮現不良反應。結論複方鱉甲軟肝片治療慢性乙型肝炎患者安全、有效，可以改善肝纖維化指標。
목적：평고복방별갑연간편치료만성을형간염환자대혈청간섬유화지표적영향。방법장304례만성을형간염분위시험조219례화대조조85례。급여시험조구복복방별갑연간편，대조조구복안락화섬환，료정24 w。채용ELISA법검측투명질산（HA)、점련단백（LN）、Ⅳ형효원（c-Ⅳ）화Ⅲ형전효원（PCⅢ）。결과재치료24 w결속시，경중의증후료효전분석집（FAS）분석，시험조현효솔위72.9%，우우대조조적56.8%（P=0.004）；시험조총유효솔위89.3%，우우대조조적80.7%（P=0.029）；시험조혈청간섬유화지표현효솔위35.3%，우우대조조적22.2%（P=0.016）；치료후시험조혈청투명질산（HA）수평하강료（87.4±111.2） ng/mL，우우대조조하강적（61.2±66.2） ng/mL（P=0.01），량조혈청LN、c-Ⅳ、PCⅢ수평변화무통계학차이（P>0.05）；량조간공능지표복상솔차이무통계학의의（P＞0.05）；시험조미발현불량반응。결론복방별갑연간편치료만성을형간염환자안전、유효，가이개선간섬유화지표。
Objective To evaluate the efficacy of Compound Biejia Ruangan Tablets (RGP) on preventing the progression of liver fibrosis in patients with chronic hepatitis B (CHB). Methods 304 patients with CHB were divided into treatment group(n=219),and control group (n=85). The patients in treatment group were given RGP orally at dose of 4 tablets,3 times daily,and in control group given Anluo Huaxian pills (ALHX) orally,at dose of 6 g,2 times daily. The serum hyaluronan,laminin,collagen type Ⅳ,and PCⅢ levels were detected by ELISA. Results At the end of 24-week treatment,the significant improvement of Chinese medicine symptom as assessed by curative effect full analysis set (FAS) in treatment group was 72.9%,higher than 56.8%(P=0.004) in control group;the total efficiency in treatment group was 89.3%,higher than 80.7% in control group(P=0.029);The curative effect analysis of four items for liver fibrosis showed that the significant efficiency in treatment group was 35.3%,better than 22.2% in control group (P=0.016);the total effective rate was no statistically significantly different between the two groups;For serum liver fibrosis indexes,the hyaluronic acid in treatment group fell by (87.4±111.2) ng/mL,better than that in control group,which fell(61.2±66.2) ng/mL after treatment (P=0.01);The changes of serum laminin,typeⅣcollagen and pro-collagen Ⅲ in the two groups had no statistical differences (P>0.05);The normalization rates of liver function indexes after treatment had no statistically significant difference between the two groups(P>0.05);In terms of safety,we found no adverse reaction in the two groups. Conclusion It is safe and effective to treat patients with CHB by RGP,which will improve the symptoms,and decrease serum liver fibrosis indexes.
